世界中医药

目的：观察两合汤对肝郁阴虚型不寐病临床疗效。方法：将符合条件的42例肝郁阴虚型不寐病患者按照随机数字表法平均分为2组，每组21人。治疗组给予两合汤口服，对照组给予天王补心汤口服。经过4周的治疗，观察对照组和治疗组治疗前后的匹兹堡睡眠质量指数(Pittsburgh Sleep Quality Index score，PSQI)评分,中医症候评分变,不良反应发生情况和睡眠改善情况。疗程为4周。结果：1）匹兹堡睡眠质量指数(PSQI)的变化：经过4周治疗后，2组的PSQI总分较治疗前均有所下降。经过4周治疗，2组间的PSQI总分之间比较亦差异有统计学意义(P<0.05)，治疗组(两合汤组)优于对照组。2）中医证候积分的变化,经过4周治疗后，2组与治疗前相比差异有统计学意义(P<0.05),治疗组优于对照组。治疗组治疗后入睡困难,多梦易醒等症状均得到明显改善。结果表明2组差异有统计学意义(P<0.05)，说明治疗组对失眠的改善效果优于对照组。3）安全性评价：2组治疗过程中均无不良反应事件发生。表明两合汤安全性高。结论：两合汤对肝郁阴虚型不寐病临床效果良好且无不良反应,值得临床推广应用。

English Summary:

To observe the clinical efficacy of Lianghe Decoction in treating insomnia patients with stagnation of liver qi and yin deficiency. Methods:A total of 42 insomnia patients with stagnation of liver qi and yin deficiency syndrome were divided into two groups according to the random number table, each group having 21 patients. The treatment group was given Lianghe Decoction, while the control group was given Celestial Emperor Heart-Tonifying Decoction. After four weeks’treatment, the Pittsburgh Sleep Quality Index score(PSQI) and the TCM (traditional Chinese medicine) Syndromes Scale were evaluated. Results:PSQI in the two groups both dropped after four weeks’treatment while there were significant differences in the overall evaluation between the two groups (P<0.05). The treatment group had better results than the control group; TCM Syndromes Scale in the two groups showed significant differences after four weeks’treatment (P<0.05) while there were significantly better results in the treatment group (P<0.05). Some syndromes like difficulty in falling asleep and waking up easily in treatment group were improved. There were no adverse effects in both two groups, which showed the two decoctions were safe. Conclusion:The clinical efficacy of Lianghe Decoction in treating insomnia patients with stagnation of liver qi and yin deficiency is clear and safe, which is worthy of clinical promotion.

查看全文查看/发表评论下载PDF阅读器